Abstract
This report summarized the discussion on:
- Routine PCV13 use among adults >65 years old: summary of evidence, cost‐effectiveness, and GRADE conclusions
- Considerations for PCV13 use among adults and policy options
- Recommendations for PCV13 use among adults
- Agenda & Minutes
- Americas
- United States of America
- Pneumococcal disease